Charles River Laboratories International Inc., which provices drug-research services, gave 2013 earnings guidance that was below Wall Street’s expectations. In addition, the Wilmington company now expects its 2012 per-share earnings to come in between the low end and the midpoint of its previously estimated range of $2.68 to $2.73. The company expects sales to grow by 3 to 5 percent next year, and that non-GAAP earnings per share would be in the range of $2.80 to $2.90. The analyst consensus for 2013 is $3.02, RTTNews reported.